Amy J Johnson

Amy J Johnson

Johnson & Johnson Co. - New Jersey / United States
Others
AD Scientific Index ID: 4390824
-
person_outline Amy J Johnson's MOST POPULAR ARTICLES
1-) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia New England Journal of Medicine 369 (1), 32-42, 2013
2-) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia New England Journal of Medicine 374 (4), 323-332, 2016
3-) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 117 (23), 6287-6296, 2011
4-) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 (2), 591-594, 2011
5-) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ...Blood 117 (2), 591-594, 20118832011